Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affitech AS
Affitech Announces Achievement of Significant Milestone in Antibody Discovery Collaboration
May 23rd, 2008
Affitech AS, the human antibody therapeutics company announced another successfully completed milestone in its long-term antibody discovery partnership with Peregrine Pharmaceuticals. At the 2008 Annual Meeting of the American Association for Cancer Research (AACR), Peregrine presented preclinical studies demonstrating that PGN635, a fully human antibody discovered as part of their collaboration, exhibits anti tumor efficacy by targeting phosphatidylserine (PS). Peregrine currently has an anti-PS antibody, bavituximab, that is in phase II clinical trials for the treatment of breast and lung cancers and in a phase I study for the treatment of chronic HCV infection. ...
Source: Health Business Week (2008-05-23)
|
